Highlights of This Issue 1415

REVIEW

1417 Malignant Peripheral Nerve Sheath Tumors: From Epigenome to Bedside
Justin Korfhage and David B. Lombard

1429 Evaluation of Tumor Cell–Tumor Microenvironment Component Interactions as Potential Predictors of Patient Response to Napabucasin
An-Yun Chang, Eric Hsu, Jaimin Patel, Yiqun Li, Minjie Zhang, Haruhsia Iguchi, and Harry A. Rogoff

CANCER GENES AND NETWORKS

1435 Somatic Hypermutation of the YAP Oncogene in a Human Cutaneous Melanoma
Xiaomeng Zhang, Tian Zhong Tang, Ismael A. Vergara, Youfang Zhang, Pacman Szeto, Lie Yang, Christopher Mintoff, Andrew Colebatch, Lachlan McIntosh, Katrina A. Mitchell, Evangeline Shaw, Helen Rizos, Georgina V. Long, Nicholas Hayward, and Mark Shackleton

1450 The PKR-Like Endoplasmic Reticulum Kinase Promotes the Dissemination of Myc-Induced Leukemic Cells
Jun Gai, Konstantins V. Katlinski, Constantinos Koumenis, J. Alan Diehl, and Serge Y. Fuchs

1459 TP53 Mutation by CRISPR System Enhances the Malignant Potential of Colon Cancer
Sho Watanabe, Kishiro Tsuchiya, Ryu Nishimura, Tomoaki Shirasaki, Nobuhiro Katsukura, Shuji Hibiya, Ryuichi Okamoto, Tetsuya Nakamura, and Mamoru Watanabe

1468 The Pluripotency Regulator PRDM14 Requires Hematopoietic Regulator CBFA2T3 to Initiate Leukemia in Mice
Lauren J. Tracey, Travis Brooke-Bisschop, Pascal W. T. C. Jansen, Eric I. Campos, Michel Vermeulen, and Monica J. Justice

CANCER ”-OMICS”

1493 Characterization of HCC Mouse Models: Towards an Etiology-Oriented Subtyping Approach
Juliane Friemel, Lukas Frick, Kristian Unger, Michelle Egger, Rossella Parrotta, Yannick T. Böge, Arlind Adili, Michael Karin, Tom Luedde, Mathias Heikenwalder, and Achim Weber

CELL FATE DECISIONS

1503 GSK2801, a BAZ2/BRD9 Bromodomain Inhibitor, Synergizes with BET Inhibitors to Induce Apoptosis in Triple-Negative Breast Cancer
Samantha M. Bevill, Jose F. Olivares-Quintero, Noah Scialy, Brian T. Golitz, Darshan Singh, Adriana S. Beltran, Naim U. Rashid, Timothy J. Stuhlmler, Andrew Hale, Nathaniel J. Moorman, Charlene M. Santos, Steven P. Angus, Jon S. Zawistowski, and Gary L. Johnson

1519 Hyperphosphorylation of CDH1 in Glioblastoma Cancer Stem Cells Attenuates APC/CDH1/CDC20 Activity and Pharmacologic Inhibition of APC/CDH1/CDC20 Compromises Viability
Kuntal De, Treg M. Grubb, Abigail A. Zalenski, Kayla E. Pfaff, Debanjali Pal, Shubhra Majumder, Matthew K. Summers, and Monica Venere

METABOLISM

1531 Adaptation to HIF1α Deletion in Hypoxic Cancer Cells by Upregulation of GLUT14 and Creatine Metabolism
Alessandro Vali, Matteo Morotti, Christos E. Zois, Patrick K. Albers, Tomoyoshi Soga, Katharina Feldinger, Roman Fischer, Martin Fejno, Alan McIntyre, Esther Bridges, Syed Haider, Francesca M. Bufla, Dilair Baban, Miguel Rodriguez, Oscar Yanes, Hannah J. Whittington, Hannah A. Lake, Sevasti Zervou, Craig A. Lygate, Benedikt M. Kessler, and Adrian L. Harris
About the Cover

Hippo pathway signaling through hyperactivated YAP has been shown to promote aggressive phenotypes in uveal melanoma, but its role in cutaneous melanoma is poorly understood. In this issue, Zhang and colleagues demonstrate that YAP is upregulated and hyperactivated in most premalignant melanocytic nevi and malignant melanoma lesions, and it presents a potential therapeutic target in a subset of melanoma patients. Moreover, the authors provide clinical evidence for the first known activating YAP mutations in human cancer. See the article beginning on page 1435 for more information.

The cover depicts co-immunofluorescence staining of a clinical case of cutaneous melanoma (red, Melan-A; green, YAP1; blue, nuclei stained with DAPI).